Response-adapted ultra-low dose radiation achieves complete response in 90% of patients with orbital indolent B-cell lymphomas
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. Results were presented today at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.
This study, led by Chelsea C. Pinnix, M.D., Ph.D., associate professor of Radiation Oncology, is the...
Allison Institute establishes internal advisory council of MD Anderson experts
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the establishment of its internal advisory...
Lung, breast and colorectal cancer tackled in latest Texas computational oncology collaboration
Three new cancer research projects have been chosen to receive seed funding as part of the program in Oncological Data and Computational Science...
MD Anderson and ARTIDIS announce strategic alliance to advance nanomechanical technology platform for optimizing cancer treatment
The University of Texas MD Anderson Cancer Center and ARTIDIS AG today announced a strategic alliance to investigate ARTIDIS technology as a novel treatment-optimization tool for patients with solid tumors in several distinct indications.
Supported by previous scientific evidence, the ARTIDIS atomic force microscopy (AFM) technology rapidly captures the physical properties of cells and their microenvironment at the nanometer level...
